Navigation Links
Kanzius Cancer Research Foundation Earns $1 for Each New Facebook Fan

ERIE, Pa., April 14, 2011 /PRNewswire/ -- In an effort to match last year's $250,000 Pepsi Refresh Everything grant, the Kanzius Cancer Research Foundation (KCRF) launched the "Repeat the Wave" Campaign on April 1 raising over $40,000 and adding more than 4,000 new Facebook fans in thirteen days. Until April 30, KCRF is increasing awareness and raising additional funds for research of the Kanzius Non-Invasive Radiowave Cancer Treatment by asking the public to "like" them on Facebook.

An anonymous donor has agreed to donate one dollar for each new KCRF Facebook fan as well as match fifty cents for each dollar donated to the Foundation. After a Facebook user likes the page, they are then encouraged to "Spread the Wave" by inviting all of their Facebook friends to also "like" the Kanzius Cancer Research Foundation page. The campaign urges KCRF supporters to use a special landing page,, and invite their social networks to spread the wave just like last April, when Internet users and Facebook fans voted KCRF's project as the most "refreshing idea" during the Pepsi Refresh Everything contest. Since the start of this campaign, KCRF has increased support on local, national and global levels.

"A year ago, we embarked on a journey to 'Spread the Wave' and thanks to overwhelming community support, we won the Pepsi contest resulting in a grant of $250,000 to educate new audiences; this has truly transformed our foundation," said Mark A. Neidig, Sr., executive director of Kanzius Foundation. "Today, I am once again humbled by the tremendous support for the 'Repeat the Wave' campaign.  No doubt, everyone has been touched by cancer in some way.  The 'Kanzius Way' of treating cancer non-invasively and without side effects is why we won the grant last year and today, this timely message is still refreshing and worth repeating!"

About the Kanzius Cancer Research Foundation

The Kanzius Cancer Research Foundation is a 501(c) (3) non-profit organization with a mission to create national and global awareness of the potentials of the Kanzius Non-invasive Radiowave Cancer Treatment, and to help accelerate the speed at which this research progresses to human trials. The goal of KCRF is to raise money to support ongoing research grants.  Pancreatic, liver and colorectal cancers in test subjects are undergoing extensive research in Houston and Pittsburgh; additional, ongoing studies are currently focused on breast, leukemic, lung, melanomic and prostate cancers. John Kanzius' sophisticated radio transmission machine is being manufactured in Erie, Pa.  For more information about the Kanzius research, visit

SOURCE Kanzius Cancer Research Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):